Abbvie Inc. · NYSE:ABBV
Abbvie — J.P. Morgan Healthcare Conference 2013
17 slides from Abbvie's conference presentation, Jan 8, 2013
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference BILL CHASE EXECUTIVE VP, FINANCE & CFO
Slide 2: Disclaimer and Forward-Looking Statement
Disclaimer and Forward‐Looking Statement This presentation and its contents are confidential and may not be reproduced, redistributed, published or passed on to any other person person, directly or indirectly indirectly, in whole or in part part, for any purpose purpose. This presentation is neither
Slide 3: A Leading Global Biopharmaceutical Company
A Leading Global Biopharmaceutical Company TRADITIONAL BIOPHARMA BIOTECH PHARMA The stability, global scale The focus, creativity, and resources to effectively culture and agility to commercialize scientific achieve breakthrough discoveries for patients science J.P. Morgan Healthcare Conference| Jan
Slide 4: A Large-Cap, Research-Based Biopharmaceutical Leader
A Large‐Cap, Research‐Based Biopharmaceutical Leader • Sustainable leadership positions across specialty‐focused specialty focused commercial portfolio PROVEN • Robust cash flow powering $1.60 annualized dividend EXECUTION • Focus on efficient operations MEETS • Financial policy balancing short and
Slide 5: Four Core Strategies for Accelerating Long-Term Growth
Four Core Strategies for Accelerating Long‐Term Growth AbbVie Growth Strategies ACHIEVE • Continue to drive sustainable growth through new indications, 1 HUMIRA’S increased penetration, penetration geographic expansion and share gains FULL POTENTIAL • Leverage strong growth of the anti‐TNF market •
Slide 6: A Mix of Growth Brands and Sustainable, Differentiated Leaders
A Mix of Growth Brands and Sustainable, Differentiated Leaders Leading growth brands driving continued strong performance Numerous sustainable products, each with unique attributes that create category leadership J.P. Morgan Healthcare Conference| January 8, 2013 | Company Confidential © 2013 6
Slide 7: Humira: #1 Global Anti-TNF
Humira: #1 Global Anti‐TNF #1 gglobal anti‐TNF, ggrowingg double‐digits g 15 years of clinical data 9 approved indications Additional indications in late‐stage development 670,000 patients worldwide J.P. Morgan Healthcare Conference| January 8, 2013 | Company Confidential © 2013 7
Slide 8: Humira: A Leading Biopharmaceutical Product Positioned for Continued Strong Growth
Humira: A Leading Biopharmaceutical Product Positioned for Continued Strong Growth Biologics Market Growth • US biologics market: Growing mid‐ to high‐single digits • EU biologics market: Major EU markets continue to grow double‐digits • Humira: Growth continues to outpace the markets Increasing Sha
Slide 9: Differentiated Products with Established Leadership
Differentiated Products with Established Leadership Humira is the #1 anti‐TNF biologic worldwide AndroGel A d G l 1.62% 1 62% holds th leading market share position h ld the iti ini the th fast‐growing testosterone replacement market Lupron is the #1 hormone therapy for the palliative treatment of a
Slide 10: Pipeline Focused on Areas of Significant Patient Need
Pipeline Focused on Areas of Significant Patient Need Late‐Stage Pipeline Highlights Mid‐Stage Pipeline Highlights 10 Phase III programs underway 10+ programs underway Hepatitis C Virus CLL Affects 170MM worldwide Accounts for 25% of all leukemias Schizophrenia Immunology Affects 1% of world’s popul
Slide 11: Late-Stage Pipeline Program Highlights
Late‐Stage Pipeline Program Highlights Compound Details HCV IFN‐Free Combination • Comprehensive Phase III program underway HCV Genotype 1 • Highly potent, well‐tolerated and easy‐to‐administer interferon‐free treatment with the ability to deliver very high cure rates • Phase IIb AVIATOR results sho
Slide 12: Mid-Stage Pipeline Program Highlights
Mid‐Stage Pipeline Program Highlights Compound Details ABT‐199 (Partner: Roche/Genentech) • Pioneering Bcl‐2 science; more selective, next generation compound, ABT‐199 being Chronic Lymphocytic Leukemia, Lupus evaluated in CLL and lupus • Phase III CLL expected to begin in 2013; Phase I Lupus study
Slide 13: Early-Stage Program Highlights
Early‐Stage Program Highlights Early‐Stage • Next‐generation protease and NS5A inhibitors recently entered human studies Virology Candidates • Evaluating early‐stage next‐generation oral Early‐Stage candidates, including internal JAK1 inhibitor Immunology gy Candidates • DVD‐Ig platform enables two
Slide 14: HCV: A Significant Global Opportunity
HCV: A Significant Global Opportunity Key Market Dynamics and Patient Considerations • 170MM people infected worldwide; more than 4MM newly diagnosed annually • Only a fraction of diagnosed patients receive treatment • Hundreds of thousands of patients are waiting for safer, more effective options •
Slide 15: Rapidly Advancing HCV Program
Rapidly Advancing HCV Program Regimen Combination for Phase III Evaluation* Program Overview 12‐Week Duration • Highly potent potent, well well‐tolerated tolerated and easy‐to‐administer easy to administer interferon‐ interferon Treatment Regimen free treatment with the ability to deliver very high
Slide 16: Strong Financial Foundation
Strong Financial Foundation • Strong liquidity position - Initial cash balance of ~$7.2BN - Pro forma debt of ~$15.7BN ABBVIE TO BEGIN - S Strong iinvestment grade d ratings i OPERATIONS WITH STRONG CAPITAL • Cash flow allocation STRUCTURE AND − Targeting annual dividend of $1.60 per share LIQUIDITY
Slide 17: A New Biopharmaceutical Investment Opportunity
A New Biopharmaceutical Investment Opportunity Experienced management team with track record of strong execution World’s #1 anti‐TNF biologic, Humira, positioned for continued strong growth Sustainable leadership positions across specialty portfolio Strongg global g footprint p with accelerating g g